A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

Inclusion criteria

• Age ≥ 19
• Patients who understood the contents and purpose of this trial and signed informed consent form
• Patients with essential hypertension and dyslipidemia

Exclusion criteria

• Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP
• Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg
• Concomitant administration of cyclosporine
• Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy
• Hereditary angioedema or medical history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor blockers
• Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin
• CPK normal range > 2 times
• Secondary hypertension and suspected secondary hypertension
• Orthostatic hypotension with symptoms
• Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)
• Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times)
• Active gout or hyperuricemia(uric acid ≥ 9mg/dL)
• IDDM or uncontrolled type 2 diabetes mellitus (HbA1c > 9%)
• Ventricular arrhythmia
• Medical history

• Severe heart disease(heart failure of NYHA class III-IV)
• Severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertensive encephalopathy, transient cerebral ischemic attack(TIA)
• Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant stenosis in aortic valve or mitral valve
• Ischemic heart disease(myocardial infarction, angina) within 6months
• Angioplasty or coronary artery bypass graft(CABG) surgery within 6months